Eidos Therapeutics (EIDX) Upgraded to “Hold” by Zacks Investment Research
According to Zacks, “Eidos Therapeutics, Inc. is a clinical stage biopharmaceutical company. It discovers and develops novel oral therapy for the treatment of diseases caused by transthyretin amyloidosis. Eidos Therapeutics, Inc. is based in San Francisco, United States. “
A number of other research analysts have also recently commented on the stock. JPMorgan Chase & Co. upgraded shares of Eidos Therapeutics from a neutral rating to an overweight rating in a research note on Wednesday, February 27th. BMO Capital Markets began coverage on shares of Eidos Therapeutics in a research note on Friday, February 22nd. They set an outperform rating and a $28.00 price target for the company. Finally, ValuEngine cut shares of Eidos Therapeutics from a buy rating to a hold rating in a research note on Monday, December 17th. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The stock has a consensus rating of Buy and a consensus price target of $27.00.
Eidos Therapeutics (NASDAQ:EIDX) last announced its quarterly earnings results on Monday, April 15th. The company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.01). As a group, analysts expect that Eidos Therapeutics will post -1.99 earnings per share for the current fiscal year.
In other news, CFO Christine Siu sold 11,913 shares of Eidos Therapeutics stock in a transaction that occurred on Tuesday, March 19th. The shares were sold at an average price of $19.66, for a total value of $234,209.58. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Several large investors have recently bought and sold shares of the company. BlackRock Inc. raised its stake in shares of Eidos Therapeutics by 57.9% in the fourth quarter. BlackRock Inc. now owns 1,149,364 shares of the company’s stock valued at $15,814,000 after acquiring an additional 421,666 shares during the last quarter. Aisling Capital Management LP bought a new position in shares of Eidos Therapeutics in the fourth quarter valued at approximately $15,461,000. Victory Capital Management Inc. bought a new position in shares of Eidos Therapeutics in the fourth quarter valued at approximately $2,835,000. Vanguard Group Inc. raised its position in Eidos Therapeutics by 297.3% in the 3rd quarter. Vanguard Group Inc. now owns 198,673 shares of the company’s stock worth $1,983,000 after purchasing an additional 148,673 shares during the last quarter. Finally, Vanguard Group Inc raised its position in Eidos Therapeutics by 297.3% in the 3rd quarter. Vanguard Group Inc now owns 198,673 shares of the company’s stock worth $1,983,000 after purchasing an additional 148,673 shares during the last quarter. Institutional investors own 30.15% of the company’s stock.
Eidos Therapeutics Company Profile
Eidos Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) amyloidosis (ATTR). It is developing AG10, an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR.
Recommended Story: Hedge Funds
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Eidos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eidos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.